- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of Novel Agents for Idiopathic Pulmonary Fibrosis: Phase 2a Clinical Trial and phase 2b approval of BBT-877, autotaxin inhibitor, in IPF patients | ||||||
| Small Molecules | Idiopathic pulmonary fibrosis | Autotacxin | Phase 2 | Bridge Biotherapeutics, Inc. | RS-2023-00219938 | ||
| 2 | Clinical Trial Development of A Novel Small Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Treatment | ||||||
| Small Molecules | IPF | Prolyl-tRNA synthetase (PRS) | Phase 2 | Daewoong Pharmaceutical Co., Ltd. | RS-2022-00166689 | ||